16 December 2019 - Janssen announced today that Health Canada, following a priority review, has approved Erleada (apalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer.

This approval is based on results from the Phase 3 TITAN study, which achieved statistical significance in the dual primary endpoints of overall survival and radiographic progression-free survival at the first pre-planned interim analysis.

Read Janssen press release